The 2023 data indicate that Croatia leads in European anxiolytic medicine sales, valued at 226.3 million USD PPP, showing a growth of 1.79% from prior years. Portugal follows with a value of 88.2 million but experienced a slight decline of 0.045%. Hungary, Denmark, Luxembourg, and Estonia exhibit varied sales, with Estonia marking a rise of 2.29% and Iceland showing the highest positive growth of 2.83%. Conversely, Denmark showed a significant drop of 4.42%. Over five years, sales have generally stabilized, with minimal compound annual growth rates.
Future trends to watch include:
- Diversification of anxiolytic products driven by innovative treatments.
- Potential regulatory changes impacting availability and pricing.
- Market expansion opportunities in emerging European economies.
Top countries in Anxiolytic Medicine Sales by Country
| # | 7 Countries | Million US Dollars PPP | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Croatia | 226.3 | 2023 | +1.21% | +1.79% | View data |
| 2 | 2 Portugal | 88.2 | 2023 | 0% | -0.045% | View data |
| 3 | 3 Hungary | 17.3 | 2023 | +16.11% | -2.66% | View data |
| 4 | 4 Denmark | 7.1 | 2023 | -4.05% | -4.42% | View data |
| 5 | 5 Luxembourg | 2.8 | 2023 | 0% | -1.37% | View data |
| 6 | 6 Estonia | 2.8 | 2023 | 0% | +2.29% | View data |
| 7 | 7 Iceland | 2.3 | 2023 | 0% | +2.83% | View data |
